To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

United States117th CongressHR-7640House of Representatives
Updated: May 3, 2022

Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  2. Introduced in House

All available records shown.